At £15.59, GSK’s (LSE: GSK) share price is 14% lower than the 52-week high of £18.23 it hit back in May. I reckon now could be a good time to take a closer look at the FTSE 100 pharmaceutical giant.
It has been a volatile year for the stock. But as a long-term investor, if I sense a strong buying opportunity, I’m content with riding out some short-term ups and downs. With that, let’s dig a little deeper into GSK.
Short-term challenges
There’s one main reason I see that explains why its share price has fallen. It’s linked to potential litigation surrounding Zantac, a heartburn drug that was taken off shelves in 2019 after being linked to causing cancer.
Earlier this year, a judge in Delaware ruled in favour of around 72,000 lawsuits related to Zantac and its link to cancer to go forward.
This came as a shock decision. When it was revealed, it wiped almost £7bn off GSK’s value in just one day. Its share price has failed to recover since.
GSK now faces the potential of thousands of costly court cases. That clearly has investors worried. Analysts at Citi have said it could cost the firm up to £3bn in settlement fees.
Long-term growth
But looking past that, what could drive long-term growth for the business? Well, I see plenty of encouraging factors.
Its Q2 update highlighted its growing R&D pipeline. The business has now secured approvals or filings for 10 “major opportunities”. It also reported “positive data” from seven phase III trials.
In its results, the business upgraded its 2024 guidance. Sales growth should now come in between 7-9%. Core operating profit growth should sit between 11-13%.
Attractive value
Looking at its price-to-earnings (P/E) ratio, the stock looks like good value for money. It trades on a P/E of 16. As the chart below highlights, that’s significantly cheaper than industry peers such as AstraZeneca, which trades on a P/E of 38.2.
Created with TradingView
To go with that, the stock has a healthy dividend yield of 3.8%. Not only is that higher than the FTSE 100 average (3.6%), but, as seen below, it’s also higher than AstraZeneca’s 1.8% yield.
Created with TradingView
My move
With the stock trading below its 52-week high, I think now could be a smart time for investors to take a closer look at GSK and consider buying some shares.
Despite the potential challenges it could face in the months ahead, I think there’s a lot to like about the business.
Legal complications are always a threat when investing in pharma stocks. And no doubt further negative updates relating to Zantac could send its share price down again.
However, it’s a stock with a solid valuation. Plus, as it carries on growing its pipeline, I think the business is well-positioned to post strong growth in the coming years. I’ll be delving deeper into the FTSE 100 constituent in the weeks ahead.
The post The GSK share price is 14% off its 52-week high. Time to consider buying? appeared first on The Motley Fool UK.
5 stocks for trying to build wealth after 50
Inflation recently hit 40-year highs… the ‘cost of living crisis’ rumbles on… the prospect of a new Cold War with Russia and China looms large, while the global economy could be teetering on the brink of recession.
Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.
Claim your free copy now
More reading
2 boring but beautiful picks I think could make great additions to a Stocks and Shares ISA
1 FTSE 100 bargain stock I love
These boring but beautiful picks will always have a place in my Stocks and Shares ISA
As GSK’s share price drops 15%, should I buy, sell, or hold?
I’m considering 3 top UK dividend stocks for my portfolio this July
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
